Quarter
Charts

PAVMED INC. — Key Metrics

2 years of history · ending 2025-12-31 · SEC EDGAR

Income StatementCash FlowBalance SheetKey Metrics

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$1
Book Value Per Share
$51
Free Cash Flow Per Share
$-8
Cash Per Share
$2
Revenue Per Share
$0
OCF Per Share
$-8
Return on Equity
2.5%
Return on Assets
1.2%
Return on Invested Capital
-109.5%
Current Ratio
0.17
Quick Ratio
0.17
Asset Turnover
0.00
Days Sales Outstanding
2.19
Days Payables Outstanding
1135.18
Days Inventory On Hand
—
Cash Conversion Cycle
—
R&D / Revenue
6326.8%
SBC / Revenue
2404.2%
Capex / Revenue
43.7%
Working Capital
$-12M
Net Current Asset Value
$-14M
Invested Capital
$34M
OCF / Net Income
-12.98
FCF / Net Income
-13.06
Accruals Ratio (Sloan)
14.4%
Net Debt
$-2M
Net Debt / EBITDA
0.07
Interest Coverage
-1038.38
Cash Coverage
-247.90
Capex Coverage
-167.94
Tangible Common Equity
$34M
TCE / Total Assets
87.5%
NOPAT
$-17M
Cash ROIC
-33.3%
WC / Revenue
-17295.8%
Capex / D&A
0.30
Reinvestment Rate
0.3%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
124.2%
Stock Price (FY-end)
$7
Market Cap
$4M
P/E Ratio
11.09
P/S Ratio
62.61
P/B Ratio
0.13
P/TB Ratio
0.13
Enterprise Value
$3M
EV / Sales
40.95
FCF Yield
-117.8%
Shareholder Yield
-38.4%
R&D Yield
101.1%
Capex Yield
0.7%
Graham Number
$26
Shares Variation (YoY)
-69.2%
Beta (5Y)
1.38
Cost of Equity
11.4%
52W High
$25
52W Low
$7
Trailing Return 1Y
-65.9%
Trailing Return 5Y
-99.2%
F-Score (Piotroski)
3.00
Z-Score (Altman)
-11.40

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

PAVMED INC. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes9.90%13.20%6.60%-6.10%-8.40%-1.10%
Foreign Rate Differential-5.80%-0.60%-1.00%2.70%-4.80%0.00%
Other Adjustments-0.80%0.10%-15.20%—1.90%—
Valuation Allowance Change-24.30%-33.70%-12.70%45.60%37.60%—
Tax Law Change—————0.00%
Effective Tax Rate0.00%———0.00%0.00%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)——————
Income Taxes Paid (Cash)——————